



FORM PTO-449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 1 OF 1
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 0136/1E154US1
APPLICANT: Tae-Yeon KIM et al.SERIAL NO: 09/989,621
FILING DATE: 11-20-01

RECEIVED

FEB 14 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------	----------------------------	-------------	-------------	-----------------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS SUBCLASS</u>	<u>TRANSLATION</u> <u>YES NO</u>
-------------------------------	----------------------------	-------------	----------------	-----------------------	-------------------------------------


OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)***EXAMINER
INITIALS

1. W. I. White et al., "Antibody and Cytotoxic T-lymphocyte Responses to a Single Liposome-Associated Peptide Antigen", *Vaccine*, 13(12):1111-1122 (1995).
2. F. Zhou and L. Huang, "Monophosphoryl Lipid A Enhances Specific CTL Induction by a Soluble Protein Antigen Entrapped in Liposomes, *Vaccine*, 11(11):1139-1144 (1993).
3. Barbara Reherrmann et al., "Cytotoxic Lymphocyte Responsiveness after Resolution of Chronic Hepatitis B Virus Infection", *The Journal of Clinical Investigation*, 97(7): 1655-1665 (1996).
4. Ramin Nayersina et al., "HLA A2 Resitrected Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes during Hepatitis B Virus Infection", *The Journal of Immunology*, 150(10):4659-4671 (1993).

EXAMINER: Apie RobinsonDATE CONSIDERED: 12/29/03*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(O&D Forms/PTO-17)



02-11-02

GP/1653

EXPRESS MAIL CERTIFICATE

Date 2/8/02 Label No. EC 039137185-us

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

B.W. LEE
Name (Print)

B.W. Lee
Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 0136/1E154US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tae-Yeon KIM, et al.

Serial No.: 09/989,621

Art Unit: TBA

Confirmation No.: TBA

Filed: November 20, 2001

Examiner: TBA

For: LIPOSOMES COMPRISING PEPTIDE ANTIGENS DERIVED FROM X
PROTEIN OF HEPATITUS B VIRUS

RECEIVED

FEB 14 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449. Copies of the documents listed thereon can be found in

the parent application of this application, U.S. Serial No. 09/051,006, filed March 30, 1998.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed within three months of the filing of the application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search,

will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: February 8, 2002



Anna Löqvist, Ph.D.
Limited Recognition Under
37 C.F.R. §10.9(b) (see enclosure)
Representative for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, NY 10022
(212) 527-7700